UC Davis Health’s Interstitial Lung Disease (ILD) Program, within the nationally ranked Division of Pulmonary, Critical Care and Sleep Medicine, is a leader in the field of ILD and member of the Pulmonary Fibrosis Foundation Care Center Network. The Program has established distinction and dedication in state-of-the-art care advanced therapies for patients with a diagnosis of Interstitial lung Disease. In existence for close to 30 years, the program currently sees over 400 patients with a diagnosis of pulmonary fibrosis. The program has a multidisciplinary approach lead by nationally renowned pulmonologists with a team of radiologists, nurse specialists, pharmacists and respiratory therapists all working together to provide the highest level care to patients with pulmonary fibrosis. We emphasize a patient centered approach and aim to support and educate patients and their families about their disease.
Our multi-disciplinary team, which includes physicians, nurses, respiratory therapists, pharmacists and clinical research coordinators provides comprehensive care for patients with ILD. In addition to our clinical program, our team engages in a wide variety of research initiatives, including clinical trials, translational investigation and basic science research.
Our team provides state-of-the-art care for patients with interstitial lung disease. All patients evaluated through our program receive a standardized work-up, including laboratory testing, imaging, pulmonary function testing and oxygen needs assessment. Management plans are established with patients upon diagnosis and clinical trial information provided for those interested in enrollment. ILDs managed through our clinic include:
Research Programs, Clinical Trials and Support Groups
Our team is constantly researching new therapies to better care for our patients. Below are a few ways we support our patients.
Our team includes several NIH-funded investigators focused on basic and translational ILD research. We maintain a large ILD biobank the houses blood samples from patients consenting to participation in our registry. These samples are used to identify new ILD biomarkers and test novel therapies.
We are actively involved in clinical trials evaluating new therapies and tools for improving patient care and the treatment of lung diseases.
The Pulmonary Fibrosis Foundation (PFF) is dedicated to promoting earlier recognition and diagnosis of pulmonary fibrosis and ensuring that patients receive the highest quality healthcare. As part of that commitment, over the past three years the PFF has worked with the PF medical community to establish the PFF Care Center Network, where people with PF can find experienced medical professionals who understand their disease and support services to improve the quality of their lives.
Our board-certified pulmonology specialists have expertise in interstitial lung disease, including longstanding experience in the diagnosis and management of pulmonary fibrosis. Our team engages in weekly multi-disciplinary conferences and maintains close ties with referring pulmonologists to ensure seamless care for our patients.
Namita Sood, M.D., F.C.C.P
Director
Professor of Medicine, Internal Medicine-Pulmonary and Critical Care Medicine
Brian Morrissey, M.D.
Associate Director
Clinical Professor, Internal Medicine-Pulmonary and Critical Care Medicine
Bradley Sanville, M.D.
Assistant Professor, Division of Pulmonary, Critical Care, and Sleep Medicine
Kirsten Hanson, B.S.N., R.N.
Nurse Coordinator
Yi Shi
Pharmacist
Richard White, R.R.T.
Respiratory Therapist
Gina Brandau, R.R.T.
Respiratory Therapist
Maya Juarez, M.S.
Clinical Research Coordinator
Sarah Ruth Natera
Clinical Research Coordinator
Paul Radion Yegorov
Clinical Research Coordinator